Trial Profile
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Olokizumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms CREDO 3
- Sponsors R-Pharm
- 15 Nov 2023 Results (n=1944) assessing the changes in serum adiponectin levels in patients with active rheumatoid arthritis during treatment with IL-6 inhibitor olokizumab from NCT02760368; NCT02760407; NCT02760433 trials, presented at the ACR Convergence 2023.
- 14 Nov 2022 Results presented at the ACR Convergence 2022
- 15 Sep 2022 Efficacy and safety results and patients-reported outcomes published in the Annals of the Rheumatic Diseases